The global ophthalmic drugs market was valued at $25bn in 2018. The market was dominated by the Retinal Disorder drug submarket which held 43% of the global ophthalmic drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 215-page report you will receive 83 tables and 72 figures– all unavailable elsewhere.
The 215-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global ophthalmic drugs market revenue forecasts from 2019-2029
• Global ophthalmic drugs market revenue forecasts from 2019-2029, by submarket:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs
• Revenue forecasts from 2019-2028 of the leading ophthalmic drugs:
• Alphagan
• Avastin
• Azopt
• Eylea
• Lucentis
• Lumigan & Ganfort
• Restasis
• Vigamix
• Xalatan/Xalacom
• Other Ophthalmic Drugs
• Our report provides an overview, revenue forecast from 2019-2029 of the ophthalmic drugs segment, revenue forecast from 2019-2029 of the leading drugs, product pipeline and SWOT analysis, for these companies:
• Akorn
• Allergan
• Bayer
• Novartis
• Pfizer
• Regeneron
• Roche
• Santen Pharmaceuticals
• Senju
• Valeant
• Our study discusses the selected emerging ophthalmic drug manufacturers:
• Acucela
• Aerie Pharmaceuticals
• Aerpio Therapeutics
• Alimera Sciences
• Amakem
• Ampio Pharmaceuticals
• Chengdu Kanghong Pharmaceutical
• Eleven Biotherapeutics
• EyeGate Pharmaceuticals
• Gene Signal
• Icon Bioscience
• MacuCLEAR
• Neurotech
• Omeros
• OphthaliX /Can-Fite BioPharma
• Ophthotech
• Otsuka Pharmaceutical
• pSivida Corp.
• RXi Pharmaceuticals
• Shire
• ThromboGenics
• Our report provides these Qualitative Analysis:
• Drivers and Restraints of the Global Ophthalmic Drugs market
• SWOT Analysis of selected leading companies
• Porter’s Five Forces Analysis of the Global Ophthalmic Drugs Market
• Key questions answered by this report:
• How is the ophthalmic drugs market evolving?
• What is driving and restraining the ophthalmic drugs market?
• What are the market shares of each segment of the overall ophthalmic drugs market in 2018?
• How will each ophthalmic drug submarket grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each ophthalmic drugs submarket develop from 2018- 2029?
• Which individual therapies will prevail and how will these shifts be responded to?
• What will be the main growth driver of the overall market from 2019-2029?
• Who are the leading players in each regional market and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry evolve during the period between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the ophthalmic drugs market. You find data, trends and predictions.
Buy our report today Pharma Leader Series: Top 30 Ophthalmic Drug Manufacturers 2019-2029: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Ophthalmic Drugs
2.1. The Pharmaceutical Industry: Very Brief Overview
2.2. The Global Burden of Eye Disease
2.3. Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
3. Ophthalmic Drugs Market, 2019-2029
3.1 Global Ophthalmic Drugs: Market Overview
3.1.1 The World Ophthalmic Drugs Market in 2018
3.2 Global Ophthalmic Drugs: Market Forecast 2019-2029
3.3. Leading Ophthalmic Drugs
3.4 Leading Companies in the Global Ophthalmic Drugs Market
3.4.1 Top 30 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2019-2029
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2019-2029
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2019-2029
3.5.3 Glaucoma Drugs Market: Sales Forecast 2019-2029
3.5.4 Dry Eye Drugs Market: Sales Forecast 2019-2029
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2019-2029
3.6 How Will Market Shares Change to 2029?
3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2019-2029
3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints
4. Leading US Ophthalmic Drugs Manufacturers 2019-2029
4.1 Allergan: Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis
4.1.1.2 Restasis: Sales Forecast 2019-2029
4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
4.1.1.4 Lumigan and Ganfort: Sales Forecast 2019-2029
4.1.1.5 Refresh Brand Products: The Range
4.1.1.6 Alphagan/Alphagan P and Combigan: Extended Lifecycle
4.1.1.7 Alphagan/Alphagan P and Combigan: Sales Forecast 2019-2029
4.1.1.8 Acular: New Forms Receiving FDA Approvals
4.1.1.9 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Edema
4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline
4.1.3 Allergan: Ophthalmic Revenue Forecast 2019-2029
4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2019-2029
4.1.4 Allergan: SWOT Analysis
4.2 Pfizer Overview
4.2.1 Pfizer: Ophthalmic Product Portfolio
4.2.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
4.2.1.2 Xalatan/Xalacom: Sales Forecast 2019-2029
4.2.2 Pfizer: Ophthalmic Product Pipeline
4.2.3 Pfizer: Revenue Forecast 2019-2029
4.2.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2019-2029
4.2.4 Pfizer: SWOT Analysis
4.3 Regeneron Overview
4.3.1 Regeneron: Ophthalmic Product Portfolio
4.3.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.3.1.2 Eylea: US Sales Forecast 2019-2029
4.3.2 Regeneron: Ophthalmic Product Pipeline
4.3.3 Regeneron: Revenue Forecast 2019-2029
4.3.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2019-2029
4.3.4 FDA Approves Zaltrap (aflibercept)
4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.3.6 Regeneron: SWOT Analysis
4.4 Akorn Overview
4.4.1 Akorn: Ophthalmic Product Portfolio
4.4.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
4.4.1.2 Cosopt/Cosopt PF: Acquired from Merck
4.4.2 Akorn: Revenue Forecast 2019-2029
4.4.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2019-2029
4.4.3 Akorn: SWOT Analysis
5. Leading European Ophthalmic Drug Manufacturers, 2019-2029
5.1 Bayer Overview
5.1.1 Bayer: Ophthalmic Product Pipeline
5.1.2 Eylea: non-US Sales Forecast 2019-2029
5.1.3 Bayer: Revenue Forecast 2019-2029
5.1.3.1 Bayer: Ophthalmic Drugs Market Share Forecast 2019-2029
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: Still a Leading Drug in AMD
5.2.1.2 Lucentis: Non-US Sales Forecast 2019-2029
5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2018- 2029
5.2.1.5 Vigamox: Competes with Alcon’s Moxeza
5.2.1.6 Vigamox: Sales Forecast 2019- 2029
5.2.1.7 Azopt: Marketed in Major Markets
5.2.1.8 Azopt: Sales Forecast 2019 - 2029
5.2.1.9 Jetrea: Sales Revenues Fall Short
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.2.2.2 AKB-9778 (Aerpio Therapeutics)
5.2.3 Novartis: Revenue Forecast 2019 - 2029
5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2019-2029
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.1.1 Lucentis: US Sales Forecast 2019-2029
5.3.1.2 Avastin: Off-Label Use for Wet AMD Cannibalising Lucentis Sales
5.3.1.3 Avastin: Sales Forecast 2019 - 2029
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.2.1 Lampalizumab (RG7417)
5.3.3 Roche: Revenue Forecast 2019-2029
5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2019-2029
5.3.4 Roche: SWOT Analysis
6. Leading Asia-Pacific Ophthalmic Drugs Manufacturers 2019-2029
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2019-2029
6.1.1.2 Hyalein
6.1.1.3 Hyalein: Sales Forecast 2019-2029
6.1.1.4 Cosopt: Non-US Sales Forecast 2019-2029
6.1.1.5 Tapros/Taflotan: Sales Forecast 2019-2029
6.1.1.6 Diquas: Sales Forecast 2019-2029
6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
6.1.1.8 Cravit: Sales Forecast 2019-2029
6.1.1.9 Alesion: Sales Forecast 2019-2029
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2019-2029
6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2019-2029
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.1.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y-39983 (SNJ-1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2019-2029
6.2.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2019-2029
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.1.1 Lotemax: New Formulation Launch Expected in 2016
6.3.1.2 Lotemax: Sales Forecast 2019-2029
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.2.1 Vesneo (Latanoprostene Bunod)
6.3.2.2 Brimonidine tartarate 0.0025% for Eye Whitening (Valeant)
6.3.3 Valeant: Revenue Forecast 2019-2029
6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2019-2029
6.3.4 Valeant: SWOT Analysis
6.3.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
6.3.4.2 Valeant: Difficult End to 2015 Puts Company Future in Doubt
7. Emerging Ophthalmic Drug Manufacturers in 2018
7.1 Acucela
7.2 Aerie Pharmaceuticals
7.3 Aerpio Therapeutics: Developing AKB-9778
7.4 Alimera Sciences
7.4.1 Iluvien: Increasing Geographical Reach and Increasing Sales
7.4.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.5 Amakem
7.6 Ampio Pharmaceuticals
7.7 Chengdu Kanghong Pharmaceutical
7.8 Eleven Biotherapeutics
7.9 EyeGate Pharmaceuticals
7.10 Gene Signal
7.10.1 Aganirsen: Preventing Corneal Graft Rejection
7.11 Icon Bioscience
7.12 MacuCLEAR
7.12.1 MC-1101: a Potential Therapy for Dry AMD
7.13 Neurotech
7.14 Omeros
7.15 OphthaliX (Can-Fite BioPharma)
7.16 Ophthotech
7.16.1 Fovista: Potential Game-Changer in AMD
7.16.2 Fovista: Significant Improvement on Lucentis in Phase II Trials
7.16.3 Zimura: Complement C5 Inhibitor
7.17 Otsuka Pharmaceutical
7.18 pSivida Corp.
7.19 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.20 Shire
7.20.1 Lifitegrast (SHP606) for Dry Eye
7.20.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.21 ThromboGenics
7.21.1 Jetrea (ocriplasmin)
7.21.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline
7.22 Sun Pharmaceutical Industries Ltd. (XELPROS)
8. Qualitative Analysis of the Ophthalmic Drugs Market 2019-2029
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]
9. Conclusions
9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
9.2 The World Ophthalmic Drugs Market in 2019
9.2.1 Leading Ophthalmic Drugs Market Segments
9.2.2 Leading Ophthalmic Drugs
9.2.3 Leading Ophthalmic Drug Companies
9.3 World Ophthalmic Drugs Market Forecast 2019-2029
9.4 The Future of the Ophthalmic Drugs Market?
9.4.1 Increasing Revenue Concentration among Specialist Companies
9.4.2 The Rise of Generics
9.4.3 Small Companies Can Have a Big Impact
9.4.4 What Will Succeed in the Ophthalmic Drugs Market?
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 ICD-10 Classification of Visual Impairment
Table 2.2 Drug Treatments for Glaucoma, 2018
Table 2.3 Drug Treatments for AMD, 2018
Table 2.4 Drug Treatments for Ocular Allergy, 2018
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2018
Table 2.6 Selected Drug Treatments for Eye Infections, 2018
Table 2.7 Clinical Trial Phases
Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2018 and 2019
Table 3.2 Global Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2018
Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs
Table 3.5 Top 30 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2018
Table 3.6 Global Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2018, 2023 and 2029
Table 4.1 Allergan: Overview, 2019
Table 4.2 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2018
Table 4.3 Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.5 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.6 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.7 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.8 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2019-2029
Table 4.9 Pfizer: Overview, 2019
Table 4.10 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.11 Pfizer: Ophthalmic Drugs Revenue($m), AGR (%) and CAGR (%), 2019-2029
Table 4.12 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.13 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2019-2029
Table 4.14 Regeneron: Overview, 2019
Table 4.15 Regeneron: Eylea Revenue ($m), AGR (%) and CAGR (%) 2019-2029
Table 4.16 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.17 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.18 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2019-2029
Table 4.19 Akorn: Overview, 2019
Table 4.20 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.21 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 4.22 Akorn: Ophthalmic Drugs Market SWOT Analysis, 2019-2029
Table 5.1 Bayer: Overview, 2019
Table 5.2 Bayer: Eylea Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 5.3 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 5.4 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 5.5 Novartis: Overview, 2019
Table 5.6 Novartis: Lucentis Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 5.7 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 5.8 Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2019-2029
Table 5.9 Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2019-2029
Table 5.10 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019 - 2029
Table 5.11 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 5.12 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2019 - 2029
Table 5.13 Roche: Overview, 2019
Table 5.14 Roche: Lucentis Revenue ($m), AGR (%) and CAGR (%) 2019- 2029
Table 5.15 Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR (%), 2019 - 2029
Table 5.16 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 5.17 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 5.18 Roche: Ophthalmic Drugs Market SWOT Analysis, 2019- 2029
Table 6.1 Santen: Overview, 2019
Table 6.2 Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2019
Table 6.3 Santen: Eylea Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.4 Santen: Hyalein Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.5 Santen: Cosopt Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.7 Santen: Diquas Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.8 Santen: Cravit Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.9 Santen: Alesion Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.10 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.11 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.12 Santen: Ophthalmic Drugs Market SWOT Analysis, 2019-2029
Table 6.13 Senju: Overview, 2019
Table 6.14 Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2019
Table 6.15 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.16 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.17 Senju: Ophthalmic Drugs Market SWOT Analysis, 2019-2029
Table 6.18 Valeant: Overview, 2019
Table 6.19 Valeant: Lotemax Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.20 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2019-2029
Table 6.21 Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2019-2029
Table 6.22 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2019-2029
Table 7.1 Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country
Table 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), Market Share (%). 2018
List of Figures
Figure 1.1 Global Causes of Visual Impairment (% of Cases), 2018
Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015 and 2026
Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2019
Figure 2.1 Estimated Global Blindness and Visual Impairment (% of people), 2018
Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2018
Figure 2.3 Global Causes of Visual Impairment (% of Cases)
Figure 2.4 Global Causes of Blindness (% of cases)
Figure 2.5 Classification of Glaucoma, 2018
Figure 3.1 The Global Ophthalmic Drugs Market Forecast by Sector, 2018 and 2019
Figure 3.2 The Global Ophthalmic Drugs Market Forecast by Sector, 2018 and 2019
Figure 3.3 Global Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
Figure 3.4 Top 9 Ophthalmic Drugs: Revenues ($m), 2018
Figure 3.5 Top 9 Ophthalmic Drugs: Market Share (%), 2018
Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs: Revenues ($m), 2018
Figure 3.7 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2018
Figure 3.8 Retinal Disorders Drugs Market Forecast: Revenue ($m), 2019-2029
Figure 3.9 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2019-2029
Figure 3.10 Glaucoma Drugs Market Forecast: Revenue ($m), 2019-2029
Figure 3.11 Dry Eye Drugs Market Forecast: Revenue ($m), 2019-2029
Figure 3.12 Other Ophthalmic Drugs Market Forecast: Revenue ($m), 2019-2029
Figure 3.13 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2018
Figure 3.14 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2023
Figure 3.15 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2029
Figure 3.16 Ophthalmic Drugs Market Drivers & Restraints 2019-2029
Figure 4.1 Allergan: Restasis Revenue ($m) and AGR (%), 2019-2029
Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2019-2029
Figure 4.3 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2019-2029
Figure 4.4 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 4.5 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 4.6 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2019-2029
Figure 4.7 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), 2019-2029
Figure 4.8 Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 4.9 Regeneron: Eylea Revenue ($m) and AGR (%), 2019-2029
Figure 4.10 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 4.11 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 4.12 Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 4.13 Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 5.1 Bayer: Eylea Revenue ($m) and AGR (%), 2019- 2029
Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019- 2029
Figure 5.3 Bayer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 5.4 Novartis: Lucentis Revenue ($m), AGR (%), 2019- 2029
Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR (%), 2019-2029
Figure 5.6 Novartis: Vigamox Revenue ($m) and AGR (%), 2019- 2029
Figure 5.7 Novartis: Azopt Revenue ($m) and AGR (%), 2019- 2029
Figure 5.8 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), 2019- 2029
Figure 5.9 Novartis: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 5.10 Roche: Lucentis Revenue ($m) and AGR (%), 2019- 2029
Figure 5.11 Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2019-2029
Figure 5.12 Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 5.13 Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2018
Figure 6.2 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2018
Figure 6.3 Santen: Eylea Revenue ($m) and AGR (%), 2019-2029
Figure 6.4 Santen: Hyalein Revenue ($m) and AGR (%), 2019-2029
Figure 6.5 Santen: Cosopt Revenue ($m) and AGR (%), 2019-2029
Figure 6.6 Santen: Tapros/Taflotan Revenue ($m) and AGR (%), 2019-2029
Figure 6.7 Santen: Diquas Revenue ($m) and AGR (%), 2019-2029
Figure 6.8 Santen: Cravit Revenue ($m) and AGR (%), 2019-2029
Figure 6.9 Santen: Alesion Revenue ($m) and AGR (%), 2019-2029
Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 6.11 Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 6.13 Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 6.14 Valeant: Lotemax Revenue ($m) and AGR (%), 2019-2029
Figure 6.15 Valeant: Ophthalmic Drugs Revenue ($m) and AGR (%), 2019-2029
Figure 6.16 Valeant: Ophthalmic Drugs Market Share (%), 2019-2029
Figure 7.1 Gene Signal: Ophthalmic Drug Pipeline Progress
Figure 7.2 Ophthotech: Ophthalmic Drug Pipeline Progress
Figure 7.3 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress
Figure 7.4 Shire: Ophthalmic Drug Pipeline Progress
Figure 8.1 Porter’s Five Force Analysis
Figure 9.1 The Global Ophthalmic Drugs Market Forecast by Sector, 2018 and 2019
Abbott Laboratories (Abbott)
Abbvie
Actavis
Acucela
Advanced Vision Research (acquired by Akorn)
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Pharmaceuticals
Alcon (subsidiary of Novartis)
Alimera Sciences
Allergan
Allegro Ophthalmics
Altheos
Amakem
Ampio Pharma
Asahi Glass
AstraZeneca
Aton Pharma (acquired by Valeant)
Banyu Pharmaceutical (part of Merck)
Bausch and Lomb (subsidiary of Valeant)
Bayer
Bayer Yakuhin (Japanese subsidiary of Bayer)
BioDiem
Bicycle Therapeutics
Biogen Idec
BioInvent International
Biovail Corporation (part of Valeant)
Bristol-Myers Squibb
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Chiron Corportation (part of Novartis)
Chugai Pharmaceutical (part of Roche)
CIBA VISION (part of Novartis)
Ciba-Geigy (part of Novartis)
Colby Pharmaceutical Company (Colby)
CoMentis
Daiichi Sankyo
Eleven Biotherapeutics
Eli Lilly and Company (Lilly)
EyeGate Pharmaceuticals
Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
Fougera Pharmaceuticals (acquired by Novartis)
Gene Signal
Genentech (subsidiary of Roche)
Genzyme (subsidiary of Sanofi)
Gilead Sciences
GSK
ICN Pharmaceuticals (original Valeant company)
Icon Bioscience
Inamed Corporation (subsidiary of Allergan)
Inception Sciences, Inc.
InSite Vision
Inspire Pharmaceuticals (acquired by Merck)
ISTA Pharmaceuticals (part of Valeant)
Jerini AG
Jerini Ophthalmic (part of Jerini AG)
Johnson & Johnson
Kestrel Ophthalmics
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuCLEAR
MacuSIGHT, Inc.
MAP Pharmaceuticals (acquired by Allergan)
Meda
Medicis Corporation (acquired by Valeant)
Merck & Co. (Merck)
MerLion Pharmaceuticals
MSD K.K. (part of Merck)
Mylan Pharmaceuticals
Mystic Pharmaceuticals
Neurotech
NicOx
Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
NovaBay Pharmaceuticals
Novagali Pharma (acquired by Santen)
Novartis
Novo (subsidiary of Novo Nordisk)
Novo Nordisk
Oakwood Laboratories
OcuSciences
Omeros
Onyx Pharmaceuticals
OphthaliX (part-owned by Can-Fite BioPharma)
Ophthotech
OPKO Health
Ora
OSI Pharmaceuticals
Othera Pharmaceuticals (acquired by Colby)
Otsuka Pharmaceutical
Oxford BioMedica
OXiGENE
Parke-Davis (subsidiary of Pfizer)
PDL BioPharma
Pfizer
Pharmacia (acquired by Pfizer)
Potentia Pharmaceuticals
Premacure
Procter & Gamble
pSivida
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
RetroSense Therapeutics
ReVision Therapeutics
Roche
RXi Pharmaceuticals
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co. (Santen)
SARcode Bioscience
Schering-Plough (part of Merck)
Senju
Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)
Senju USA Inc. (subsidiary of Senju)
Shire
Sirion Therapeutics
Sirna Therapeutics
Sirnaomics
SkinMedica (subsidiary of Allergan)
Spark Therapeutics
Symphony ViDA
Takeda Pharmaceutical
Teva
The Patent Board
ThromboGenics
Upjohn (acquired by Pfizer through Pharmacia)
Valeant Pharmaceuticals
Ventana Medical Systems (acquired by Roche)
Versant Ventures
Warburg Pincus LLC
Warner-Lambert (acquired by Pfizer)
Watson Pharmaceuticals
Wyeth Pharmaceuticals (part of Pfizer)
List of Other Organizations Mentioned in the Report
A*STAR Institute for Infocomm Research (Singapore)
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
Council of Europe
Emory University
European Medicines Agency (EMA)
Foundation Fighting Blindness (FFB) (US)
Health Canada
Institute of Experimental Medicine (Russia)
Institute of Ocular Pharmacology, Texas A&M (US)
Institute of Ophthalmology, University College London (UK)
Intellectual Property Appellate Board (India)
International Diabetes Federation
Internet Archive
Japan Patent Office (JPO)
Mayo Clinic
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Monash University
National Eye Institute (NEI) (US)
National Health Service (NHS) (UK)
National Institute for Health and Care Excellence (NICE) (UK)
NHS Scotland
Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)
Novartis Venture Funds (NVF) (part of Novartis)
Ophthalmology External Research Unit (part of Pfizer)
Ophthrisi (GSK research unit)
Rinat (Pfizer research unit)
Texas Emerging Technology Fund
Therapeutic Goods Administration (TGA) (Australia)
Tokyo University of Science
United States Food and Drug Administration (FDA)
University of Florida
University of Kentucky
University of Melbourne
University of Michigan
US Preventive Services Task Force (USPSTF)
US Securities and Exchange Commission (SEC)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
